Skip to main content

Table 5 Change in clinical and functional status between baseline and one year by APR levels

From: Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year

  Neither APR elevated APR levels discordant Both APR elevated P value
  n = 2,520 n = 1,058 n = 650  
mHAQ 0.01 ± 0.31 -0.03 ± 0.40 -0.10 ± 0.43 <0.0001
CDAI -2.40 ± 10.87 -3.92 ± 12.37 -7.68 ± 14.19 <0.0001
Tender joints -0.69 ± 5.48 -1.28 ± 5.81 -2.75 ± 6.98 <0.0001
Swollen joints -1.12 ± 5.11 -1.49 ± 5.53 -2.58 ± 5.95 <0.0001
Patient global assessment -2.38 ± 25.21 -4.90 ± 27.78 -11.29 ± 30.11 <0.0001
MD global assessment -4.21 ± 17.30 -6.45 ± 19.78 -12.57 ± 23.19 <0.0001
  1. APR, acute phase reactant; mHAQ, modified Health Assessment Questionnaire; CDAI, Clinical Disease Activity Index.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us